Cell-based proteome profiling of potential dasatinib targets by use of affinity-based probes.
暂无分享,去创建一个
Shao Q Yao | S. Yao | Chong-Jing Zhang | Haibin Shi | Haibin Shi | Chong-Jing Zhang | Grace Y J Chen | Grace Y. J. Chen
[1] V. Turk,et al. Selective activity-based probes for cysteine cathepsins. , 2008, Angewandte Chemie.
[2] S. Harrison,et al. Crystal structures of c-Src reveal features of its autoinhibitory mechanism. , 1999, Molecular cell.
[3] P. Cohen,et al. The specificities of protein kinase inhibitors: an update. , 2003, The Biochemical journal.
[4] S. Yao,et al. Small molecule microarray-facilitated screening of affinity-based probes (AfBPs) for gamma-secretase. , 2009, Chemical communications.
[5] Georges von Degenfeld,et al. Noninvasive optical imaging of cysteine protease activity using fluorescently quenched activity-based probes. , 2007, Nature chemical biology.
[6] M. Wenk,et al. Click-based synthesis and proteomic profiling of lipstatin analogues. , 2010, Chemical communications.
[7] S. Sze,et al. Novel application of electrostatic repulsion-hydrophilic interaction chromatography (ERLIC) in shotgun proteomics: comprehensive profiling of rat kidney proteome. , 2010, Journal of proteome research.
[8] E. Haura,et al. Src kinases as therapeutic targets for cancer , 2009, Nature Reviews Clinical Oncology.
[9] M. Wittekind,et al. The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. , 2006, Cancer research.
[10] Pengyu Yang,et al. Multicolor, one- and two-photon imaging of enzymatic activities in live cells with fluorescently Quenched Activity-Based Probes (qABPs). , 2011, Journal of the American Chemical Society.
[11] B. Cravatt,et al. Mechanism-based profiling of enzyme families. , 2006, Chemical reviews.
[12] Nathanael Gray,et al. Factors underlying sensitivity of cancers to small-molecule kinase inhibitors , 2009, Nature Reviews Drug Discovery.
[13] Arthur J. Olson,et al. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading , 2009, J. Comput. Chem..
[14] M. Vojtěchová,et al. Regulation of c-Src activity by the expression of wild-type v-Src and its kinase-dead double Y416F-K295N mutant. , 2006, Archives of biochemistry and biophysics.
[15] James D. Griffin,et al. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia , 2007, Nature Reviews Cancer.
[16] Bin Fang,et al. A chemical and phosphoproteomic characterization of dasatinib action in lung cancer , 2010, Nature chemical biology.
[17] Karunakaran A Kalesh,et al. The use of click chemistry in the emerging field of catalomics. , 2010, Organic & biomolecular chemistry.
[18] Young‐Tae Chang,et al. Functional profiling, identification, and inhibition of plasmepsins in intraerythrocytic malaria parasites. , 2009, Angewandte Chemie.
[19] J. Kuriyan,et al. High yield bacterial expression of active c‐Abl and c‐Src tyrosine kinases , 2005, Protein science : a publication of the Protein Society.
[20] Chao Zhang,et al. Structure-guided development of affinity probes for tyrosine kinases using chemical genetics. , 2007, Nature chemical biology.
[21] Karunakaran A Kalesh,et al. Small molecule probes that target Abl kinase. , 2010, Chemical communications.
[22] S. Yao,et al. Microarray-assisted high-throughput identification of a cell-permeable small-molecule binder of 14-3-3 proteins. , 2010, Angewandte Chemie.
[23] P. Cole,et al. Protein tyrosine kinases Src and Csk: a tail's tale. , 2003, Current opinion in chemical biology.
[24] J. Cheng,et al. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. , 2005, Cancer research.
[25] J. Melo,et al. The molecular biology of chronic myeloid leukemia. , 2000, Blood.
[26] R. Weissleder,et al. Bioorthogonal probes for polo-like kinase 1 imaging and quantification. , 2011, Angewandte Chemie.
[27] Kinneret Keren,et al. Dynamic imaging of protease activity with fluorescently quenched activity-based probes , 2005, Nature chemical biology.
[28] S. Larson,et al. Synthesis and biological evaluation of a fluorine-18 derivative of dasatinib. , 2007, Journal of medicinal chemistry.
[29] M. Uttamchandani,et al. Activity‐Based Protein Profiling: New Developments and Directions in Functional Proteomics , 2008, Chembiochem : a European journal of chemical biology.
[30] P. Cohen. Protein kinases — the major drug targets of the twenty-first century? , 2002, Nature reviews. Drug discovery.
[31] E. Sausville,et al. Issues and progress with protein kinase inhibitors for cancer treatment , 2003, Nature Reviews Drug Discovery.
[32] M. Bogyo,et al. Enzyme activity--it's all about image. , 2004, Trends in cell biology.
[33] J. Jongstra,et al. PIM Kinase Inhibitors Downregulate STAT3Tyr705 Phosphorylation , 2010, Molecular Cancer Therapeutics.
[34] W. Lee,et al. Quantitative inhibitor fingerprinting of metalloproteases using small molecule microarrays. , 2007, Journal of the American Chemical Society.
[35] Shao Q Yao,et al. Proteome profiling reveals potential cellular targets of staurosporine using a clickable cell-permeable probe. , 2011, Chemical communications.
[36] Karunakaran A Kalesh,et al. An Improved Mechanism‐Based Cross‐Linker for Multiplexed Kinase Detection and Inhibition in a Complex Proteome , 2008, Chembiochem : a European journal of chemical biology.
[37] V. Stoll,et al. Discovery of 3H-benzo[4,5]thieno[3,2-d]pyrimidin-4-ones as potent, highly selective, and orally bioavailable inhibitors of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM) kinases. , 2009, Journal of medicinal chemistry.
[38] Morten Meldal,et al. Cu-catalyzed azide-alkyne cycloaddition. , 2008, Chemical reviews.
[39] M. Uttamchandani,et al. Inhibitor fingerprinting of matrix metalloproteases using a combinatorial peptide hydroxamate library. , 2007, Journal of the American Chemical Society.
[40] Edward W. Tate,et al. Activity-based probes: discovering new biology and new drug targets. , 2011, Chemical Society reviews.
[41] Paul A. Clemons,et al. The binding of fluorophores to proteins depends on the cellular environment. , 2011, Angewandte Chemie.
[42] J. Kornhauser,et al. Nerve Growth Factor Activates Extracellular Signal-Regulated Kinase and p38 Mitogen-Activated Protein Kinase Pathways To Stimulate CREB Serine 133 Phosphorylation , 1998, Molecular and Cellular Biology.
[43] J Mottram,et al. Intracellular targets of cyclin-dependent kinase inhibitors: identification by affinity chromatography using immobilised inhibitors. , 2000, Chemistry & biology.
[44] L. Meijer,et al. Intracellular Targets of Paullones , 2002, The Journal of Biological Chemistry.
[45] G. Superti-Furga,et al. Target profiling of small molecules by chemical proteomics. , 2009, Nature chemical biology.
[46] K. Shokat,et al. Targeted polypharmacology: Discovery of dual inhibitors of tyrosine and phosphoinositide kinases , 2008, Nature chemical biology.
[47] Ping Chen,et al. Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor , 2004, Science.
[48] C. Grütter,et al. Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc. , 2009, Journal of medicinal chemistry.
[49] Alex Matter,et al. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug , 2002, Nature Reviews Drug Discovery.
[50] O. Vitolo,et al. Amyloid β-peptide inhibition of the PKA/CREB pathway and long-term potentiation: Reversibility by drugs that enhance cAMP signaling , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[51] P. Cole,et al. Protein tyrosine kinase Csk-catalyzed phosphorylation of Src containing unnatural tyrosine analogues. , 2001, Journal of the American Chemical Society.
[52] H. Kolb,et al. The growing impact of click chemistry on drug discovery. , 2003, Drug discovery today.
[53] T. Wandless,et al. A Cell-permeable, Activity-based Probe for Protein and Lipid Kinases* , 2005, Journal of Biological Chemistry.
[54] Anna K. Schrey,et al. Comprehensive identification of staurosporine-binding kinases in the hepatocyte cell line HepG2 using Capture Compound Mass Spectrometry (CCMS). , 2010, Journal of proteome research.
[55] L. Wodicka,et al. A small molecule–kinase interaction map for clinical kinase inhibitors , 2005, Nature Biotechnology.
[56] M. Wenk,et al. Activity-based proteome profiling of potential cellular targets of Orlistat--an FDA-approved drug with anti-tumor activities. , 2010, Journal of the American Chemical Society.
[57] Anna K. Schrey,et al. Dasatinib, imatinib and staurosporine capture compounds - Complementary tools for the profiling of kinases by Capture Compound Mass Spectrometry (CCMS). , 2011, Journal of proteomics.
[58] G. Superti-Furga,et al. The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib , 2007, Proceedings of the National Academy of Sciences.
[59] M. Bogyo,et al. Activity-based probes as a tool for functional proteomic analysis of proteases , 2008, Expert review of proteomics.
[60] P. Cohen,et al. Specificity and mechanism of action of some commonly used protein kinase inhibitors , 2000 .
[61] Ping Chen,et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. , 2004, Journal of medicinal chemistry.
[62] M. Uttamchandani,et al. Next generation chemical proteomic tools for rapid enzyme profiling. , 2009, Accounts of chemical research.
[63] S. J. Taylor,et al. Autophosphorylation of Purified c-Src at its Primary Negative Regulation Site (*) , 1995, The Journal of Biological Chemistry.
[64] S. Lim,et al. A comparative study of electrostatic repulsion-hydrophilic interaction chromatography (ERLIC) versus SCX-IMAC-based methods for phosphopeptide isolation/enrichment. , 2008, Journal of proteome research.
[65] Bernhard Kuster,et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors , 2007, Nature Biotechnology.
[66] S. Chattopadhaya,et al. Developing photoactive affinity probes for proteomic profiling: hydroxamate-based probes for metalloproteases. , 2004, Journal of the American Chemical Society.
[67] Carolyn R Bertozzi,et al. Bioorthogonal chemistry: fishing for selectivity in a sea of functionality. , 2009, Angewandte Chemie.
[68] Jack Taunton,et al. A clickable inhibitor reveals context-dependent autoactivation of p90 RSK. , 2007, Nature chemical biology.
[69] T. Golub,et al. Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy , 2009, Nature Biotechnology.
[70] T. Muir,et al. Direct measurement of cathepsin B activity in the cytosol of apoptotic cells by an activity-based probe. , 2009, Chemistry & biology.
[71] Adrian Whitty,et al. The resurgence of covalent drugs , 2011, Nature Reviews Drug Discovery.
[72] Mindy I. Davis,et al. A quantitative analysis of kinase inhibitor selectivity , 2008, Nature Biotechnology.
[73] T. Iwatsubo,et al. Divergent synthesis of multifunctional molecular probes to elucidate the enzyme specificity of dipeptidic gamma-secretase inhibitors. , 2007, ACS chemical biology.
[74] S. Yao,et al. "Singapore Green": a new fluorescent dye for microarray and bioimaging applications. , 2009, Organic letters.
[75] Nasreen S Jessani,et al. Activity-based probes for the proteomic profiling of metalloproteases. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[76] T. Yeatman,et al. Role of Src expression and activation in human cancer , 2000, Oncogene.